Targeting Plaque Psoriasis (Psoriasis Vulgaris)

Enstilar is primarily used in adults and adolescents (age 12 and older) to manage Plaque Psoriasis (Psoriasis Vulgaris). It is used for managing conditions characterized by periods of heightened symptoms, which may involve localized lesions. The therapy supports the management of disruptive symptom manifestations during active phases.

---

Dual Relief for Redness, Scaling, and Discomfort

This combination therapy is centered on providing relief across symptomatic areas, including redness (erythema), scaling, and sensory discomfort (itching). It is commonly used during episodes of active flare-ups to help ease the overall symptom load, assisting in managing the visibility and appearance of plaques. This symptomatic support helps patients cope more steadily with symptom fluctuations and may contribute to improved day-to-day comfort.

---

Quick Fact: Relief for Psoriasis Symptoms

This medication helps manage symptoms related to chronic skin inflammation and irritative states. It is relevant for easing challenging symptomatic phases and often applied in scenarios that support functional stability and help manage the impact of recurrent lesions on comfort and general well-being.

Population Eligibility for Enstilar

Enstilar foam is officially indicated for use in adults and adolescents 12 years of age and older for the topical treatment of plaque psoriasis. The safety and effectiveness of the medicine have not been established in children under 12 years of age, and its use in this population is generally not recommended by regulatory authorities.

Category	Official Regulatory Status
Allowed Populations	Adults and Adolescents ge 12 years (Plaque Psoriasis)
Use Not Established	Children under 12 years of age

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with a known hypersensitivity to any component of the formulation or in patients with known disorders of calcium metabolism. Furthermore, official regulatory documents prohibit use on skin affected by specific conditions, including erythrodermic or pustular psoriasis, most viral, fungal, or bacterial skin infections, rosacea, perioral dermatitis, or areas exhibiting skin atrophy.

Restricted Use Populations

Use is not recommended on sensitive areas such as the face, groin, or axillae due to the increased risk of systemic absorption. During pregnancy and lactation, use should generally be avoided unless the potential benefit outweighs the risk. Application to the breast area is specifically contraindicated while breastfeeding.

Interactions with other medicines and products

The official interaction profile for Enstilar (calcipotriene and betamethasone dipropionate) is defined by the potential for additive systemic exposure from its two active ingredients, as formal drug interaction studies with the final foam product are not documented in regulatory sources.

Regulatory-Documented Interaction Constraints

Classification	Interacting Substances / Conditions	Constraint Basis
Prohibited Combinations	Other products containing calcipotriene or other topical corticosteroids.	Risk of additive systemic toxicity and adverse effects.
Pharmacodynamic Risk	Oral Vitamin D supplements, Calcium supplements, or thiazide diuretics.	Increased risk of hypercalcaemia due to the calcipotriene component.
Exposure Modification	Excessive exposure to natural or artificial sunlight (UV light/phototherapy).	Required restriction due to the photosensitizing effect of calcipotriene.

Regulatory agencies mandate that co-administration with other calcipotriene-containing products must be avoided to mitigate the risk of elevated blood calcium. Similarly, concurrent use of other potent topical corticosteroids is restricted to prevent additive systemic steroid exposure, which can contribute to the risk of HPA axis suppression. The profile dictates that interactions center on combinations that reinforce the pharmacological effects of the active components.

Enstilar is a topical combination product containing calcipotriene, a Vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid.

Calcipotriene acts as an agonist for the nuclear Vitamin D Receptor (VDR), forming a heterodimer complex with the Retinoid X Receptor (RXR). This complex binds to Vitamin D Response Elements (VDREs) in the nucleus of target cells, including keratinocytes and T-lymphocytes. This transcriptional modulation inhibits the proliferation of keratinocytes and promotes their terminal differentiation, thereby normalizing epidermal cell maturation. Calcipotriene also modulates immune response by suppressing T-cell activation and the production of pro-inflammatory cytokines such as IL-17 and IL-23.

Betamethasone dipropionate, a glucocorticoid, diffuses across the cell membrane to bind to the cytosolic Glucocorticoid Receptor (GR). The activated GR-ligand complex translocates to the nucleus and binds to Glucocorticoid Response Elements (GREs) on DNA. This event modifies gene transcription, leading to the upregulation of anti-inflammatory proteins and the downregulation of pro-inflammatory mediators, including phospholipase A2 and various chemokines. This collective genomic and non-genomic action mediates localized vasoconstriction and broad systemic immunosuppression at the cellular level.

How Enstilar is Used

Enstilar is a topical aerosol foam designated exclusively for cutaneous use and must not be administered in the eyes, orally, or intravaginally. The medicine is applied directly to the affected skin areas following specific, standardized instructions.

Dosing and Treatment Schedule

The standard application is once daily. The initial treatment phase is typically limited to a maximum of four weeks but should be discontinued when the condition is controlled. Dosing recommendations may vary by region; in the United States, the total quantity used should not exceed 60 grams over a 4-day interval, while the European guideline restricts daily use to no more than 15 grams. Regardless of the region, the total body surface area treated must not exceed 30%.

Procedural and Population Rules

Entity	Official Instruction
Preparation	The container must be shaken before each use.
Post-Application	Users must wash hands thoroughly after applying the foam, unless the hands are the area being treated.
Avoided Areas	Use must be avoided on the face, groin, or armpits, and occlusive dressings are prohibited without a healthcare provider's direction.
Age Minimum	The product is indicated for patients 12 years of age and older.

Following the initial short-term application, a twice-weekly maintenance pattern applied to previously affected areas on non-consecutive days is an official regimen established in several regions. If an application is missed, it should be applied when remembered, but only once on that day, before continuing the regular schedule.

Research evidence / Overview of Studies for Enstilar

The following overview describes the structure and findings of research conducted on the foam, including the kinds of studies performed, what was measured, and what remains uncertain, based on authoritative scientific and regulatory documents. This information is provided for context and is not clinical advice.

---

Evidence for Plaque Psoriasis (Psoriasis Vulgaris)

Research for the foam primarily relies on pivotal randomized controlled trials (RCTs). These are studies that compare the foam against an inactive application (vehicle-controlled trials) and against its individual components when used alone (active comparator trials). This research was studied for its use in plaque psoriasis on the body and the scalp in both adults and adolescents.

The short-term studies, which were typically limited to four weeks of application, focused on specific measurable outcomes. Researchers monitored changes in the Investigator's Global Assessment (IGA) score, which is used to measure overall disease status (e.g., clear or almost clear). The trials also measured the Psoriasis Area and Severity Index (PASI) score and recorded patient-reported outcomes, such as how symptoms like itching and scaling evolved during the study period. Findings described patterns observed in the studies related to these measured outcomes within the four-week timeframe. Research so far describes patterns where results vary among the observed populations.

---

Maintenance Research and Durability of Response

To address the long-term management of the condition, researchers conducted dedicated long-term randomized controlled trials that extended up to 52 weeks (one year). These studies were specifically designed to explore outcomes after a subject had already achieved a certain level of success during an initial short-term application phase.

The main outcome examined was the Time to First Relapse. This outcome describes the duration before a patient experienced a return or worsening of their condition after initial successful management. The evidence was collected to characterize the durability of symptom patterns when a person transitions to a less frequent application schedule. Findings describe group patterns related to sustained management over the one-year study period.

---

Evidence Gaps and Areas for Further Research

Current evidence, while based on a high level of research for the primary indication, has several acknowledged limitations. The short follow-up durations in the primary efficacy studies mean that long-term outcomes for continuous initial application are not fully established.

Research remains limited for specific subgroups of patients and for certain disease manifestations. For example, research was not conducted for conditions outside of plaque psoriasis. Studies help show what has been observed so far, but the evidence highlights what is known—and what is still uncertain—about long-term symptom management.

Common questions about Enstilar (FAQ)

Q: How is Enstilar different from a cream or ointment for psoriasis?

Regulatory documents indicate that Enstilar is a non-aqueous aerosol vehicle—a foam—which is a distinct type of formulation from traditional creams or ointments. This unique design is a different approach to topical delivery, and it has been studied for its specific penetration properties compared to traditional ointments or creams. It is regulated as a specialized dermatological preparation.

Q: Can Enstilar be used on the scalp or in the hair?

Yes, official product information confirms that Enstilar foam is indicated for the topical treatment of plaque psoriasis on the scalp and body in adults and adolescents 12 years of age and older. While the medicine should be used only on the affected areas, research evidence supports its use on the scalp.

Q: Is Enstilar known to leave a greasy residue on the skin or hair?

The foam formulation is designed to be non-aqueous and rapid-drying. However, regulatory guidance notes that for the scalp, specific recommendations related to washing may include applying a non-medicated shampoo to dry hair before rinsing to help remove residual product.

Q: What is the meaning of 'exacerbation of psoriasis' in relation to stopping treatment?

Exacerbation in this context refers to a potential rebound effect where the psoriasis condition may return or worsen after discontinuing a topical corticosteroid treatment. Official guidance notes that the post-treatment period should be carefully monitored.

Q: Can Enstilar affect blood sugar levels, especially in patients with diabetes?

Due to the potential for systemic absorption of the corticosteroid component, impaired glycaemic control of diabetes mellitus may occur. For patients with pre-existing conditions like diabetes, official warnings indicate that monitoring of blood sugar levels may be necessary during treatment.

Q: What is the significance of the betamethasone component being a high-potency corticosteroid?

The presence of a high-potency corticosteroid (betamethasone dipropionate) means there is an increased risk of clinically significant systemic effects if the medicine is used over large body areas or for too long. These effects may include HPA axis suppression (disruption of hormone balance) or manifestations resembling Cushing's syndrome.

Q: How quickly do official studies suggest people may see improvement with Enstilar?

Clinical trial results described patterns where improvements in common psoriasis symptoms such as itching, scaling, and redness were noted in some subjects starting in as early as three days of once-daily application. Findings related to these measured outcomes were observed within the four-week timeframe of the primary studies.

Q: What happens to the foam after it is sprayed onto the skin?

Enstilar is a non-aqueous aerosol designed to be rubbed gently into the affected skin until it is absorbed and quickly dries. The contents of the canister are regulated as flammable and official instructions advise keeping the product away from heat sources and open flames until the product has completely dried on the skin. The application procedure includes specific steps related to the container.

Q: Are there any official recommendations for cleansing the residue after using the foam?

Official regulatory guidance states that the hands must be washed thoroughly after application, unless the hands are the area being treated. For the application site, recommendations for washing depend on the area, such as the use of a non-medicated shampoo to help remove residue from the scalp.

Q: What are the symptoms of potential excessive absorption of the medication?

Excessive absorption may result in signs of serious conditions like Hypercalcaemia (high calcium levels) or Cushing's syndrome (too much cortisol). Symptoms associated with these conditions can potentially include increased thirst, muscle weakness, confusion, fatigue, or changes in vision.

Q: What is the risk of eye problems, such as cataracts or glaucoma, with Enstilar use?

Systemic and topical corticosteroid use may be associated with an increased risk of cataracts and glaucoma. Official information notes that if visual symptoms occur, specialized evaluation may be required.

Q: Does the medication pass into breast milk when used by a nursing mother?

According to official product information, it is not known whether the drug passes into human breast milk. Regulatory guidance states that application to the breast area is prohibited while breastfeeding.

Q: Can Enstilar cause changes in skin color, such as lightening or darkening?

Official adverse reaction lists include changes in skin color as a possible side effect, specifically skin hypopigmentation. This refers to areas of the skin losing color or appearing lighter.

Q: Are there different potencies or strengths of Enstilar available?

Official regulatory documents state that the Enstilar foam product is only available in one fixed-dose combination strength. This strength contains calcipotriene 0.005% and betamethasone dipropionate 0.064%.

Q: Does Enstilar contain alcohol or propellants that can cause irritation?

The product does contain several excipients, including butylated hydroxytoluene (E321). Official information warns that this excipient may cause local skin reactions (such as contact dermatitis) or irritation to the eyes and mucous membranes.

Q: Can the foam be sprayed out in any position, or does the can need to be upright?

Official usage instructions indicate that the foam can be sprayed holding the can in any position except horizontally (sideways). Official instructions define the proper use of the container.

The storage and disposal of Enstilar foam are strictly regulated because it is a pressurized, extremely flammable aerosol.

Storage and Handling

Constraint	Official Requirement
Temperature	Store at room temperature (20 C to 25 C / 68 F to 77 F). Do not store above 30 C.
Protection	Keep away from heat, open flames, and ignition sources. Protect the container from sunlight and temperatures exceeding 50 C (120 F), as the can may burst. Do not freeze.
Stability	Discard any unused product 6 months after the can has been opened. Do not use past the expiration date.
Safety	Keep out of the sight and reach of children. Store in the original container.

Disposal Instructions

Unused medicine and waste material must be disposed of in accordance with local requirements. The pressurized container must not be pierced or burned, even when empty.